Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

January 15, 2014

Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

clinicaltrials.gov Identifier: NCT01130246.

Preguntar a la IA

Me gusta

Guardar

Compartir

Preguntar a la IA

Me gusta

Guardar

Compartir

Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome | Synapse

Cite This Study

Nicholls et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd4a9e8557d5ab8f40ca1b https://doi.org/https://doi.org/10.1001/jama.2013.282836

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial2011 · 44 citations
2Update on acute coronary syndromes: the pathologists' view2012 · 1,033 citations
3Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors2001 · 1,751 citations
4Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes2004 · 4,943 citations
5Secretory group II phospholipase A2 in human atherosclerotic plaques1995 · 130 citations